Skip to main content

Animations

MJFF Publications

3661 - 3670 of 6568 Results
Title
Year
  • Year
  • 2017
  • 2016
  • 2016
  • 2018
  • 2011
  • 2016
  • 2022
  • 2022
  • 2016
  • 2021
  • Summary Details
    OPEN
    Title: Neuropathologic features of TOMM40 '523 variant on late‐life cognitive decline
    Journal Name: Alzheimer's & Dementia
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.jalz.2017.05.002
    Citation Count: 30
  • Summary Details
    OPEN
    Title: Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer’s Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial
    Journal Name: American Journal of Psychiatry
    Publisher: American Psychiatric Association Publishing
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1176/appi.ajp.2015.15050648
    Citation Count: 97
  • Summary Details
    OPEN
    Title: Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood‐based biomarkers
    Journal Name: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.dadm.2016.03.002
    Citation Count: 91
  • Summary Details
    OPEN
    Title: Bayesian latent time joint mixed‐effects model of progression in the Alzheimer's Disease Neuroimaging Initiative
    Journal Name: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.dadm.2018.07.008
    Citation Count: 31
  • Summary Details
    OPEN
    Title: Molecular insights into Parkinson's disease
    Journal Name: F1000 Medicine Reports
    Publisher: Faculty Opinions Ltd
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.3410/m3-7
    Citation Count: 65
  • Summary Details
    OPEN
    Title: 4-amino-7-chloroquinoline derivatives for treating Parkinson’s disease: implications for drug discovery
    Journal Name: Expert Opinion on Drug Discovery
    Publisher: Informa UK Limited
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1517/17460441.2016.1154529
    Citation Count: 19
  • Summary Details
    OPEN
    Title: A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity
    Journal Name: Neurotherapeutics
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1007/s13311-022-01199-7
    Citation Count: 25
  • Summary Details
    OPEN
    Title: Pattern and implications of neurological examination findings in autosomal dominant Alzheimer disease
    Journal Name: Alzheimer's & Dementia
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1002/alz.12684
    Citation Count: 9
  • Summary Details
    OPEN
    Title: Serum S100B Is Related to Illness Duration and Clinical Symptoms in Schizophrenia—A Meta-Regression Analysis
    Journal Name: Frontiers in Cellular Neuroscience
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fncel.2016.00046
    Citation Count: 36
  • Summary Details
    OPEN
    Title: Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model
    Journal Name: Alzheimer's & Dementia
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/alz.12463
    Citation Count: 60
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.